Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

被引:230
|
作者
McNutt, Markey C.
Lagace, Thomas A.
Horton, Jay D. [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
关键词
D O I
10.1074/jbc.C700095200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the proteinase K subfamily of subtilases, promotes internalization and degradation of low density lipoprotein receptors (LDLRs) after binding the receptor on the surface of hepatocytes. PCSK9 has autocatalytic activity that releases the prodomain at the N terminus of the protein. The prodomain remains tightly associated with the catalytic domain as the complex transits the secretory pathway. It is not known whether enzymatic activity is required for the LDLR-reducing effects of PCSK9. Here we expressed the prodomain together with a catalytically inactive protease domain in cells and purified the protein from the medium. The ability of the catalytically inactive PCSK9 to bind and degrade LDLRs when added to culture medium of human hepatoma HepG2 cells at physiological concentrations was similar to that seen using wild-type protein. Similarly, a catalytic-dead version of a gain-of-function mutant, PCSK9(D374Y), showed no loss of activity compared with a catalytically active counterpart; both proteins displayed similar to 10-fold increased activity in degradation of cell surface LDLRs compared with wild-type PCSK9. We conclude that the ability of PCSK9 to degrade LDLRs is independent of catalytic activity and suggest that PCSK9 functions as a chaperone to prevent LDLR recycling and/or to target LDLRs for lysosomal degradation.
引用
收藏
页码:20799 / 20803
页数:5
相关论文
共 50 条
  • [21] Affinity and kinetics of proprotein convertase subtilisin/kexin type 9 binding to low-density lipoprotein receptors on HepG2 cells
    Mousavi, Seyed A.
    Berge, Knut E.
    Berg, Trond
    Leren, Trond P.
    FEBS JOURNAL, 2011, 278 (16) : 2938 - 2950
  • [22] Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol
    Mohamed, Farzahna
    Mansfield, Brett
    Raal, Frederick J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (15)
  • [23] PCSK9 Inhibitors: The Next Frontier in Low-Density Lipoprotein Lowering
    Jialal, Ishwarlal
    Patel, Shailendra B.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2015, 13 (03) : 99 - 101
  • [24] α-Tocopherol modulates the low density lipoprotein receptor of human HepG2 cells
    Pal, Sebely
    Thomson, Andrew M.
    Bottema, Cynthia Dk
    Roach, Paul D.
    NUTRITION JOURNAL, 2003, 2 (1)
  • [25] α-Tocopherol modulates the low density lipoprotein receptor of human HepG2 cells
    Sebely Pal
    Andrew M Thomson
    Cynthia DK Bottema
    Paul D Roach
    Nutrition Journal, 2
  • [26] APOB SECRETION AND INTRACELLULAR LIPID CONTENT ARE MODULATED BY ANGPTL3 AND PCSK9 IN HEPG2 CELLS
    Bini, S.
    D'Erasmo, L.
    Minicocci, I.
    Di Costanzo, A.
    Tramontano, D.
    Pomanti, G.
    Covino, S.
    Arca, M.
    Pecce, V.
    ATHEROSCLEROSIS, 2023, 379
  • [27] Indole alkaloid from Nauclea latifolia promotes LDL uptake in HepG2 cells by inhibiting PCSK9
    Aggrey, Mike Okweesi
    Li Hui-Hui
    Wang Wen-Qiong
    Wang Yiping
    Xuan Li-Jiang
    PHYTOMEDICINE, 2019, 55 : 264 - 268
  • [28] Insights Into PCSK9, Low-Density Lipoprotein Receptor, and Low-Density Lipoprotein Cholesterol Metabolism: Of Mice and Man
    Stein, Evan A.
    Raal, Frederick J.
    CIRCULATION, 2013, 127 (24) : 2372 - 2374
  • [29] Bile Acids Reduce Endocytosis of High-Density Lipoprotein (HDL) in HepG2 Cells
    Roehrl, Clemens
    Eigner, Karin
    Fruhwuerth, Stefanie
    Stangl, Herbert
    PLOS ONE, 2014, 9 (07):
  • [30] Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9
    Stein, Evan A.
    Raal, Frederick
    ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 : 417 - 431